Your browser is no longer supported. Please, upgrade your browser.
DEPO Depomed, Inc. daily Stock Chart
Depomed, Inc.
Index- P/E- EPS (ttm)-1.53 Insider Own0.10% Shs Outstand62.13M Perf Week11.71%
Market Cap681.56M Forward P/E8.95 EPS next Y1.23 Insider Trans-82.68% Shs Float61.64M Perf Month5.58%
Income-94.50M PEG- EPS next Q0.09 Inst Own96.00% Short Float20.38% Perf Quarter-26.38%
Sales441.60M P/S1.54 EPS this Y-14.90% Inst Trans-5.21% Short Ratio6.77 Perf Half Y-39.02%
Book/sh3.71 P/B2.96 EPS next Y92.77% ROA-7.70% Target Price14.40 Perf Year-41.90%
Cash/sh3.13 P/C3.50 EPS next 5Y25.00% ROE-35.40% 52W Range9.38 - 27.02 Perf YTD-39.12%
Dividend- P/FCF6.15 EPS past 5Y-25.80% ROI0.00% 52W High-59.40% Beta1.15
Dividend %- Quick Ratio0.90 Sales past 5Y27.90% Gross Margin81.50% 52W Low16.95% ATR0.46
Employees490 Current Ratio1.00 Sales Q/Q-13.70% Oper. Margin5.00% RSI (14)57.07 Volatility4.74% 4.34%
OptionableYes Debt/Eq3.17 EPS Q/Q-25.30% Profit Margin-21.40% Rel Volume0.37 Prev Close11.04
ShortableYes LT Debt/Eq2.74 EarningsAug 08 AMC Payout- Avg Volume1.86M Price10.97
Recom2.50 SMA207.11% SMA500.72% SMA200-36.03% Volume687,885 Change-0.63%
May-10-17Upgrade Piper Jaffray Underweight → Neutral
Mar-29-17Reiterated RBC Capital Mkts Sector Perform $22 → $19
Mar-29-17Reiterated Mizuho Neutral $16 → $13
Feb-14-17Downgrade Mizuho Buy → Neutral $24 → $17
Dec-12-16Downgrade Piper Jaffray Neutral → Underweight
Nov-09-16Upgrade Mizuho Neutral → Buy $24
Nov-08-16Downgrade Cantor Fitzgerald Buy → Hold
Oct-04-16Downgrade Mizuho Buy → Neutral $27
Sep-19-16Reiterated Mizuho Buy $23 → $27
Jul-27-16Downgrade Piper Jaffray Overweight → Neutral
Jul-07-16Downgrade UBS Buy → Neutral $20
May-27-16Reiterated Mizuho Buy $19 → $23
May-09-16Upgrade Mizuho Neutral → Buy $19
Apr-11-16Reiterated Mizuho Neutral $14 → $18
Mar-24-16Reiterated Mizuho Neutral $16 → $14
Mar-24-16Initiated Northland Capital Outperform
Mar-10-16Initiated Leerink Partners Outperform $21
Feb-25-16Reiterated Mizuho Buy $19 → $16
Feb-24-16Reiterated WallachBeth Buy $33 → $27
Feb-23-16Reiterated RBC Capital Mkts Sector Perform $26 → $24
Jun-23-17 08:15AM  Depomed, Inc. breached its 50 day moving average in a Bullish Manner : DEPO-US : June 23, 2017 Capital Cube
Jun-16-17 03:39PM  ETFs with exposure to Depomed, Inc. : June 16, 2017 Capital Cube
Jun-14-17 09:32AM  Depomed, Inc. :DEPO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Capital Cube
Jun-11-17 02:27PM  Opioid Stocks Feel the Pressure of FDA Measures Investopedia
Jun-09-17 05:20PM  Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER -5.24%
May-26-17 02:00PM  Biotech And Pharma Industry And Stock News Investor's Business Daily
May-25-17 04:10PM  Teva Pharma, Eagle Pharma, Depomed Among Slew Getting Price Haircuts Investor's Business Daily
May-22-17 07:30AM  Depomed Announces Corporate Governance Updates GlobeNewswire
May-16-17 04:02PM  Depomed to Present at the UBS Global Healthcare Conference GlobeNewswire
May-12-17 08:00AM  Today's Research Reports on Stocks to Watch: Rexahn Pharmaceuticals and Depomed Accesswire
May-10-17 09:25PM  Edited Transcript of DEPO earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents
07:38PM  Depomed Focuses on Flagship Drug Rather Than M&A: CEO
09:34AM  Biotech Movers: Depomed Shares Tank After Losses Get Even Worse
09:29AM  Analysts' Actions -- Allergan, Coach, General Dynamics, Occidental and More
May-09-17 06:40PM  Depomed reports 1Q loss Associated Press
04:38PM  Depomed shares down 13% after earnings miss MarketWatch
04:02PM  Depomed Announces First Quarter 2017 Financial Results and Strategic Initiatives Aimed at Driving Sustainable Long-Term Growth and Shareholder Value GlobeNewswire
01:45PM  Investor Network: Depomed, Inc. to Host Earnings Call Accesswire
May-08-17 09:57AM  One Year Later: A Look At The 2016 Ira Sohn Conference Picks Benzinga
May-05-17 06:58PM  What will be the hot pick from this years Sohn hedge-fund conference? MarketWatch
May-02-17 04:05PM  Depomed to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017 GlobeNewswire
Apr-25-17 08:00AM  Depomed Announces Appointment of Sharon D. Larkin as Senior Vice President, Human Resources and Administration GlobeNewswire
Apr-13-17 05:51PM  Which Drugmakers Will Rock The Sector In Q1? Investor's Business Daily
Apr-10-17 09:30AM  STRATA Skin Sciences and Depomed Recover from Wednesday's FDA Opioid Shockwave Accesswire
Apr-05-17 05:00PM  DepoMed, Opioid Makers Fall After Trump's FDA Pick Says America's Drug Addiction Is Out of Control -5.70%
Apr-04-17 08:00AM  Depomed Announces Prepayment of $100 Million of Secured Debt Facility GlobeNewswire
Mar-31-17 09:28AM  Biotech Premarket Movers: Sage Therapeutics, Depomed, NantKwest
Mar-30-17 09:21AM  How Much Pain Will Congress Inflict on These Opioid Drugmakers' Stocks? Motley Fool -7.03%
Mar-29-17 04:19PM  Will This Biotech Survive Activist Investor Or Get Taken Over? Investor's Business Daily
11:33AM  Checkmate: Starboard Boots Depomed CEO, Two Board Members Benzinga
10:32AM  [$$] Starboard Wins More Board Seats, Replaces CEO at Depomed The Wall Street Journal
09:31AM  Biotech Premarket Movers: Vertex, Sangamo, Depomed
09:30AM  Depomed Board of Directors Shaken Up While Insys Therapeutics Appoints a New CEO Accesswire
07:01AM  Depomed Switches Out CEO and Board in Making Peace With Activist Starboard
06:48AM  DEPOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Officers
Mar-28-17 06:00PM  Depomed names new CEO, directors in deal with activist Starboard
04:52PM  [$$] Senator McCaskill Begins Probe of Prescription Opioid Marketing at The Wall Street Journal
04:32PM  Depomed names new CEO
04:23PM  Darden Restaurants and Red Hat climb; McCormick skids
04:22PM  Depomed dives as activist investor fight leads to new CEO, board members at MarketWatch
04:03PM  Depomed Announces Cooperation Agreement with Starboard Value LP Including CEO and Board Changes GlobeNewswire
01:30PM  Senator McCaskill Launching Investigation Into Opioid Drugmakers
Mar-23-17 07:07PM  CFO Says Depomed to Buy or Be Sold
Mar-06-17 08:00AM  Depomed to Present at Healthcare Conferences in March GlobeNewswire
Mar-02-17 01:04PM  DEPOMED INC Financials
Feb-27-17 10:12AM  On Generic Drugs, Patent 'Death Squads' And The Oscars at Forbes
Feb-24-17 12:15PM  DEPOMED INC Files SEC form 10-K, Annual Report
Feb-23-17 12:37PM  Depomed, Inc. :DEPO-US: Earnings Analysis: 2016 By the Numbers : February 23, 2017
10:26AM  Depomed, Inc. :DEPO-US: Earnings Analysis: Q4, 2016 By the Numbers : February 23, 2017
09:30AM  Could 2017 Prove to be a Bull Market for Biotechs? Today's Reports on Depomed and Amicus Therapeutics Accesswire
Feb-22-17 08:52AM  Argos Plummets 72%, Leads Biotech Movers +9.38%
03:08AM  Edited Transcript of DEPO earnings conference call or presentation 21-Feb-17 9:30pm GMT
Feb-21-17 08:34PM  Depomed Reports 33% Increase in 2016 Net Product Sales
04:30PM  Depomed Inc Earnings Call scheduled for 4:30 pm ET today
04:16PM  Depomed reports 4Q loss
04:11PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  Depomed Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 Depomed Inc Earnings Release - After Market Close
Feb-20-17 03:35PM  3 Companies That Need to Kick Their CEO to the Curb at Motley Fool
Feb-17-17 08:00AM  Depomed to Report Fourth Quarter Fiscal Year 2016 Financial Results on Tuesday, February 21, 2017 GlobeNewswire
Feb-14-17 05:52AM  DepoMed downgraded by Mizuho
Feb-08-17 08:00AM  Depomed to Present at Healthcare Conferences in February GlobeNewswire
Feb-07-17 01:39PM  Board Revised as Perrigo Settles With Activist Investor Starboard -5.33%
Jan-05-17 10:59AM  Depomed, Inc. Value Analysis (NASDAQ:DEPO) : January 5, 2017
Jan-04-17 09:42AM  Stocks Open Higher; Tesla Takes A Dip
08:05AM  Depomed, Inc. breached its 50 day moving average in a Bullish Manner : DEPO-US : January 4, 2017
Jan-03-17 05:16PM  What Happened in the Stock Market Today at Motley Fool +12.87%
12:09PM  Stocks Slightly Higher as Earlier Rally Fades, Dow Backs Off 20,000
11:00AM  Why Depomed Inc. Stock Spiked Today at Motley Fool
09:01AM  The Market In 5 Minutes: Oil Pushes Markets Higher To Kick Off The New Year
08:42AM  Stock Futures Rise Ahead of First Trading Day of 2017 at TheStreet
Dec-29-16 01:44PM  ETFs with exposure to Depomed, Inc. : December 29, 2016
Dec-12-16 02:52PM  Why Depomed Inc. Got Wacked Today at Motley Fool -10.25%
02:15PM  ETFs with exposure to Depomed, Inc. : December 12, 2016
08:59AM  The Market In 5 Minutes: Oil Gushes Higher
05:00AM  Purdue Strikes $790 Million Exicure Deal to Diversify at Bloomberg
Dec-02-16 08:40AM  Is Depomed Inc (DEPO) A Good Stock To Buy? at Insider Monkey
Dec-01-16 11:35AM  ETFs with exposure to Depomed, Inc. : December 1, 2016
07:45AM  What's behind put trade in Depomed
Nov-22-16 04:01PM  Depomed to Present at the Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-18-16 01:05PM  ETFs with exposure to Depomed, Inc. : November 18, 2016
Nov-17-16 11:18AM  Depomed, Inc. :DEPO-US: Earnings Analysis: Q3, 2016 By the Numbers : November 17, 2016
08:15AM  Blog Coverage Cumberland Pharma Bags Exclusive Rights for Europe Based Nordic Group Injectable Methotrexate Product Line for the US Market Accesswire
06:42AM  Executive Edge: Google Earth in VR
Nov-16-16 08:00AM  Depomed Named to Deloitte's Technology Fast 500 List of Fastest Growing Companies in North America GlobeNewswire
Nov-11-16 03:15PM  Depomed CEO has fended off multiple takeovers with strategic thinking at
08:58AM  Are Investors Right To Be Bullish On Deckers Outdoor Corp (DECK), Tower Semiconductor Ltd. (TSEM), More? at Insider Monkey
Nov-08-16 05:06PM  DEPOMED INC Files SEC form 8-K, Change in Directors or Principal Officers -16.95%
03:19PM  Why Depomed Inc.'s Shares Are Crashing 18.9% Today at Motley Fool
11:54AM  Depomed Reports Dip in Earnings, Reduces Revenue Guidance
10:25AM  Depomed Tumbles on Missed Earnings
09:29AM  Stocks to Watch: Valeant, CVS Health, Hertz Global at The Wall Street Journal
08:15AM  Analysts' Actions -- Bank of America, Depomed, Hertz, AT&T and More
06:16AM  Trade sees cap on Depomed gains
Nov-07-16 06:17PM  Edited Transcript of DEPO earnings conference call or presentation 7-Nov-16 9:30pm GMT
05:31PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:48PM  Depomed reports 3Q loss
04:31PM  Depomed plummets after disappointing sales of painkillers at MarketWatch
04:30PM  Depomed Inc Earnings Call scheduled for 4:30 pm ET today
04:00PM  Depomed Reports Third Quarter 2016 Financial Results GlobeNewswire
Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablets), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. The company sells its products to wholesalers and retail pharmacies. It also has a portfolio of license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vargas Thadd MSVP, Business DevelopmentJun 13Option Exercise6.44160,8201,036,083160,820Jun 15 04:43 PM
Vargas Thadd MSVP, Business DevelopmentJun 13Sale9.54202,3871,930,7320Jun 15 04:43 PM
HIGGINS ARTHUR JPresident and CEOJun 12Buy9.9215,000148,80015,000Jun 13 01:17 PM
Gosling Matthew MSVP, General CounselMay 11Sale11.3759,212673,30020,665May 15 08:13 PM
Vargas Thadd MSenior VP, BDMay 11Sale12.0350,000601,25041,567May 15 08:04 PM
STAPLE PETER DDirectorMar 31Option Exercise3.2715,00049,05099,403Apr 04 08:08 PM
Zenoff David BDirectorFeb 21Option Exercise3.0470,000212,90093,999Feb 23 07:03 PM
Moretti August JChief Financial Officer & SVPNov 14Option Exercise12.695,00063,45026,680Nov 15 04:43 PM
Moretti August JChief Financial Officer & SVPNov 14Sale20.845,000104,20021,680Nov 15 04:43 PM
Vargas Thadd MSenior VP, BDSep 21Sale25.0011,250281,25073,086Sep 22 06:11 PM
Moretti August JChief Financial Officer & SVPAug 10Option Exercise12.693,29741,83924,977Aug 11 05:01 PM
Moretti August JChief Financial Officer & SVPAug 10Sale21.405,000107,00021,680Aug 11 05:01 PM
Vargas Thadd MSenior VP, BDAug 10Sale20.9226,290549,98784,336Aug 11 04:56 PM